Long-acting insulin cancer link ‘inconclusive’

THE cancer scare associated with Lantus (insulin glargine) has faded further in the wake of a US government safety review, Australian experts say.

The US Food and Drug Administration (FDA) determined evidence linking Lantus and cancer was “inconclusive” due to limitations in the studies that initially sparked concern.

Three out of four observational studies published in 2009 in Diabetologia suggested an increased risk of cancer – and one, a doubling of breast cancer – with the use of long-acting insulin glargine alone.

“The evidence presented in the studies is inconclusive due to methodological limitations [and] these limitations prevent our ability to attribute the observed cancer risk to Lantus,” the FDA said.